• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性硬化性胆管炎活体供肝肝移植的当前趋势。

Current trends in living donor liver transplantation for primary sclerosing cholangitis.

机构信息

Department of Medicine, Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Transplantation. 2011 May 27;91(10):1148-52. doi: 10.1097/TP.0b013e31821694b3.

DOI:10.1097/TP.0b013e31821694b3
PMID:21544035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3155574/
Abstract

BACKGROUND

Use of the Model for End-Stage Liver Disease (MELD) score has improved the efficiency of allocating deceased donor organs for liver transplant. However, its use may reduce access to deceased donor livers for patients with primary sclerosing cholangitis (PSC) due to the weighting of the MELD score variables. To overcome such barriers in the post-MELD era, clinicians might refer patients with PSC, relative to patients without PSC, for living donor transplants more frequently.

METHODS

To test this hypothesis, we examined patients in the United Network for Organ Sharing database from December 1, 1994, to May 31, 2009.

RESULTS

In multivariable models conditioned on transplant center, patients with PSC were significantly more likely to receive a living donor transplant in both the pre-MELD (odds ratio [OR]=2.75; 95% confidence interval [CI], 2.20-3.44) and post-MELD eras (OR=4.08; 95% CI, 3.45-4.82). There was a significant interaction between PSC and post-MELD era of transplantation (OR=1.48; 95% CI, 1.11-1.97), indicating that patients with PSC were more likely to receive living donor transplants at baseline relative to patients without PSC, and that this effect was magnified following the introduction of the MELD score.

CONCLUSIONS

These findings raise the possibility that allocating livers on the basis of MELD score may have yielded the unintended consequence of increasing rates for living donor transplants for patients with PSC relative to patients with other forms of end-stage liver disease. Future research is needed to determine whether the practice of selectively transplanting patients with PSC with living donor transplants is associated with differences in clinical outcomes.

摘要

背景

使用终末期肝病模型(MELD)评分提高了分配已故供体器官进行肝移植的效率。然而,由于 MELD 评分变量的权重,其使用可能会减少原发性硬化性胆管炎(PSC)患者获得已故供体肝脏的机会。为了克服 MELD 时代后的这些障碍,临床医生可能会更频繁地将 PSC 患者与无 PSC 患者相比,推荐他们进行活体供体移植。

方法

为了验证这一假设,我们检查了 1994 年 12 月 1 日至 2009 年 5 月 31 日期间美国器官共享网络数据库中的患者。

结果

在基于移植中心的多变量模型中,PSC 患者在 MELD 前(优势比 [OR]=2.75;95%置信区间 [CI],2.20-3.44)和 MELD 后(OR=4.08;95% CI,3.45-4.82)时代更有可能接受活体供体移植。PSC 和移植后 MELD 时代之间存在显著的相互作用(OR=1.48;95% CI,1.11-1.97),这表明与无 PSC 患者相比,PSC 患者更有可能在基线时接受活体供体移植,并且在 MELD 评分引入后,这种效果更加明显。

结论

这些发现提出了一种可能性,即根据 MELD 评分分配肝脏可能产生了意想不到的后果,即与其他形式的终末期肝病患者相比,PSC 患者接受活体供体移植的比率增加。需要进一步研究来确定选择性对 PSC 患者进行活体供体移植的做法是否与临床结果的差异有关。

相似文献

1
Current trends in living donor liver transplantation for primary sclerosing cholangitis.原发性硬化性胆管炎活体供肝肝移植的当前趋势。
Transplantation. 2011 May 27;91(10):1148-52. doi: 10.1097/TP.0b013e31821694b3.
2
Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.成人对成人活体肝移植队列研究中的复发性原发性硬化性胆管炎:活体供肝与尸体供肝受者的危险因素比较
Liver Transpl. 2016 Sep;22(9):1214-22. doi: 10.1002/lt.24496. Epub 2016 Aug 2.
3
Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis.活体供肝移植可以解决原发性硬化性胆管炎患者在移植机会方面的差异。
Hepatol Commun. 2023 Aug 3;7(8). doi: 10.1097/HC9.0000000000000219. eCollection 2023 Aug 1.
4
Current policy for allocation of donor livers in the Netherlands advantages primary sclerosing cholangitis patients on the liver transplantation waiting list-a retrospective study.荷兰现行的供肝分配政策有利于肝移植等待名单上的原发性硬化性胆管炎患者:一项回顾性研究。
Transpl Int. 2018 Jun;31(6):590-599. doi: 10.1111/tri.13097. Epub 2017 Dec 5.
5
Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era.原发性硬化性胆管炎患者在终末期肝病模型时代的等待名单存活率。
Liver Transpl. 2011 Nov;17(11):1355-63. doi: 10.1002/lt.22396.
6
Modifiable patient characteristics and racial disparities in evaluation completion and living donor transplant.可改变的患者特征与评估完成情况和活体供者移植中的种族差异。
Clin J Am Soc Nephrol. 2013 Jun;8(6):995-1002. doi: 10.2215/CJN.08880812. Epub 2013 Mar 21.
7
Disparities in liver transplantation before and after introduction of the MELD score.终末期肝病模型(MELD)评分引入前后肝移植的差异。
JAMA. 2008 Nov 26;300(20):2371-8. doi: 10.1001/jama.2008.720.
8
Sex Disparity in Liver Transplant and Access to Living Donation.性别差异与肝移植和活体捐赠机会
JAMA Surg. 2021 Nov 1;156(11):1010-1017. doi: 10.1001/jamasurg.2021.3586.
9
Outcome stagnation of liver transplantation for primary sclerosing cholangitis in the Model for End-Stage Liver Disease era.终末期肝病模型时代原发性硬化性胆管炎肝移植的疗效停滞
Langenbecks Arch Surg. 2014 Dec;399(8):1021-9. doi: 10.1007/s00423-014-1214-6. Epub 2014 Jun 4.
10
Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis.原发性硬化性胆管炎患者接受死后循环死亡供肝肝移植的临床结局。
J Hepatol. 2017 Nov;67(5):957-965. doi: 10.1016/j.jhep.2017.06.027. Epub 2017 Jul 8.

引用本文的文献

1
Machine Learning Prediction Model of Waitlist Outcomes in Patients with Primary Sclerosing Cholangitis.原发性硬化性胆管炎患者等待名单结局的机器学习预测模型
Transplant Direct. 2025 Mar 28;11(4):e1774. doi: 10.1097/TXD.0000000000001774. eCollection 2025 Apr.
2
Impact of graft type on outcomes following liver transplantation for primary sclerosing cholangitis.移植物类型对原发性硬化性胆管炎肝移植术后结局的影响。
Hepatol Int. 2025 Feb;19(1):244-255. doi: 10.1007/s12072-024-10733-y. Epub 2024 Oct 30.
3
Living-Donor Liver Transplant and Improved Post-Transplant Survival in Patients with Primary Sclerosing Cholangitis.

本文引用的文献

1
Liver transplantation for cholangiocarcinoma.肝移植治疗胆管细胞癌。
Transpl Int. 2010 Jul;23(7):692-7. doi: 10.1111/j.1432-2277.2010.01108.x. Epub 2010 May 20.
2
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation.成人活体供肝与成人尸体供肝肝移植前后的住院率。
Ann Surg. 2010 Mar;251(3):542-9. doi: 10.1097/SLA.0b013e3181ccb370.
3
Re-weighting the model for end-stage liver disease score components.重新权衡终末期肝病评分组件的模型。
活体供肝肝移植与原发性硬化性胆管炎患者移植后生存率的提高
J Clin Med. 2023 Apr 11;12(8):2807. doi: 10.3390/jcm12082807.
4
Living Donor Liver Transplantation in the United States: Evolution of Frequency, Outcomes, Center Volumes, and Factors Associated With Outcomes.美国活体供肝移植:频率、结果、中心容量的演变,以及与结果相关的因素。
Liver Transpl. 2021 Jul;27(7):1019-1031. doi: 10.1002/lt.26029. Epub 2021 Jun 24.
5
British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.英国胃肠病学会和英国PSC 指南:原发性硬化性胆管炎的诊断和管理。
Gut. 2019 Aug;68(8):1356-1378. doi: 10.1136/gutjnl-2018-317993. Epub 2019 Jun 1.
6
Treatment of primary sclerosing cholangitis in children.儿童原发性硬化性胆管炎的治疗
World J Hepatol. 2019 Jan 27;11(1):19-36. doi: 10.4254/wjh.v11.i1.19.
7
Searching for Bacterial Biofilm in Recurrent Cholangitis in Primary Sclerosing Cholangitis: A Case Presentation and Introduction of an Unexplored Disease Mechanism.原发性硬化性胆管炎复发性胆管炎中细菌生物膜的探索:病例报告及一种未被探索的疾病机制介绍
J Clin Transl Hepatol. 2018 Mar 28;6(1):114-118. doi: 10.14218/JCTH.2017.00029. Epub 2017 Dec 17.
8
Indications and Outcomes in Liver Transplantation in Patients With Primary Sclerosing Cholangitis in Norway.挪威原发性硬化性胆管炎患者肝移植的适应症及预后
Transplant Direct. 2015 Oct 19;1(9):e39. doi: 10.1097/TXD.0000000000000548. eCollection 2015 Oct.
9
Recurrent primary sclerosing cholangitis in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study: Comparison of risk factors between living and deceased donor recipients.成人对成人活体肝移植队列研究中的复发性原发性硬化性胆管炎:活体供肝与尸体供肝受者的危险因素比较
Liver Transpl. 2016 Sep;22(9):1214-22. doi: 10.1002/lt.24496. Epub 2016 Aug 2.
10
Liver Transplant in Patients With Primary Sclerosing Cholangitis.原发性硬化性胆管炎患者的肝移植
Gastroenterol Hepatol (N Y). 2016 Feb;12(2):127-9.
Gastroenterology. 2008 Nov;135(5):1575-81. doi: 10.1053/j.gastro.2008.08.004. Epub 2008 Aug 15.
4
Analysis of longitudinal data to evaluate a policy change.分析纵向数据以评估政策变化。
Stat Med. 2008 Oct 30;27(24):5005-25. doi: 10.1002/sim.3340.
5
Improvement in survival associated with adult-to-adult living donor liver transplantation.成人至成人活体供肝移植相关的生存改善。
Gastroenterology. 2007 Dec;133(6):1806-13. doi: 10.1053/j.gastro.2007.09.004. Epub 2007 Sep 14.
6
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis.血清CA 19-9在预测原发性硬化性胆管炎患者胆管癌中的价值。
Dig Dis Sci. 2005 Sep;50(9):1734-40. doi: 10.1007/s10620-005-2927-8.
7
Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database.美国肝移植后的生存率:对器官共享联合网络(UNOS)数据库的疾病特异性分析
Liver Transpl. 2004 Jul;10(7):886-97. doi: 10.1002/lt.20137.
8
Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.原发性硬化性胆管炎中胆管癌的发病率及危险因素
Am J Gastroenterol. 2004 Mar;99(3):523-6. doi: 10.1111/j.1572-0241.2004.04067.x.
9
Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community.美国一个社区中原发性硬化性胆管炎的发病率、临床谱及预后
Gastroenterology. 2003 Nov;125(5):1364-9. doi: 10.1016/j.gastro.2003.07.011.
10
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis.原发性硬化性胆管炎中的肝内和肝外恶性肿瘤
J Hepatol. 2002 Mar;36(3):321-7. doi: 10.1016/s0168-8278(01)00288-4.